Glatiramer Acetate Persists at the Injection Site and Draining Lymph Nodes Via Electrostatically-induced Aggregation

Overview

Journal J Control Release

Specialty Pharmacology

Date 2018 Nov 11

PMID 30414463

Citations 9

Authors

Jimmy Y Song

Nicholas R Larson

Sharadvi Thati

Irma Torres-Vazquez

Noraida Martinez-Rivera

Natalia J Subelzu

Martin A Leon

Eduardo Rosa-Molinar

Christian Schoneich

M Laird Forrest

C Russell Middaugh

Cory J Berkland

Affiliations

Soon will be listed here.

Abstract

Glatiramer acetate (GA) is widely prescribed for the treatment of relapsing-remitting multiple sclerosis, however, the mechanism of action is still not fully understood. We investigated the structural properties of GA and examined alterations to the drug upon injection into the subcutaneous space. First, a variety of biophysical characterization techniques were employed to characterize GA in solution. GA was found to exist as alpha helices in solution with a hydrodynamic radius of ~3 nm in size. To simulate GA behavior at the site of injection, GA was injected into a solution of 1.5 MDa hyaluronic acid (HA). Visible aggregates were observed immediately upon injection and subsequent testing indicated aggregation was driven by electrostatic interactions between the positively-charged GA and negatively-charged HA. In vivo testing confirmed GA formed spherical particles in the nano- to micrometer size range, suggesting this mechanism contributes to persistence at the injection site and in draining lymph nodes. The aggregates were found to associate with glycosaminoglycans, suggesting an electrostatic mechanism of induced aggregation like the simulated injection. These novel observations may help explain the complex immunomodulatory mechanisms of GA and adverse injection site reactions seen in patients.

Citing Articles

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.

Lucas S, Thomas S Mol Pharm. 2024; 21(12):5929-5943.

PMID: 39478434 PMC: 11615947. DOI: 10.1021/acs.molpharmaceut.4c00692.

Glatiramer acetate in situ forming gel, a new approach for multiple sclerosis treatment.

Shobeirean A, Attar H, Varshochian R, Rezvanfar M Daru. 2024; 32(2):649-664.

PMID: 39225953 PMC: 11554603. DOI: 10.1007/s40199-024-00532-z.

The Role of the Intestinal Microbiome in Multiple Sclerosis-Lessons to Be Learned from Hippocrates.

El-Sayed M, Mohak S, Gala D, Fabian R, Peterfi Z, Fabian Z Biology (Basel). 2023; 12(12).

PMID: 38132289 PMC: 10740531. DOI: 10.3390/biology12121463.

Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.

Musazzi U, Franze S, Condorelli F, Minghetti P, Caliceti P Adv Healthc Mater. 2023; 12(30):e2301956.

PMID: 37718353 PMC: 11468706. DOI: 10.1002/adhm.202301956.

Changing the daily injection of glatiramer acetate to a monthly long acting product through designing polyester-based polymeric microspheres.

Molavi F, Barzegar-Jalali M, Hamishehkar H Bioimpacts. 2023; 12(6):501-513.

PMID: 36644544 PMC: 9809140. DOI: 10.34172/bi.2022.23733.

References

Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R . Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003; 100(24):14157-62. PMC: 283562. DOI: 10.1073/pnas.2336171100. View

Bagby T, Cai S, Duan S, Thati S, Aires D, Forrest L . Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. Pharmaceutics. 2013; 4(2):276-95. PMC: 3834911. DOI: 10.3390/pharmaceutics4020276. View

Windhagen A, Maniak S, Marckmann S, Lindert R, Heidenreich F, Blasczyk R . Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J Neurol Neurosurg Psychiatry. 2001; 70(3):415-6. PMC: 1737279. DOI: 10.1136/jnnp.70.3.415. View

Hildebrandt P, Copeland R, Spiro T, Otlewski J, Laskowski Jr M, Prendergast F . Tyrosine hydrogen-bonding and environmental effects in proteins probed by ultraviolet resonance Raman spectroscopy. Biochemistry. 1988; 27(15):5426-33. DOI: 10.1021/bi00415a007. View

Aharoni R, Teitelbaum D, Sela M, Arnon R . Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997; 94(20):10821-6. PMC: 23498. DOI: 10.1073/pnas.94.20.10821. View

Kurnellas M, Rothbard J, Steinman L . Self-Assembling Peptides Form Immune Suppressive Amyloid Fibrils Effective in Autoimmune Encephalomyelitis. Curr Top Behav Neurosci. 2015; 26:221-32. DOI: 10.1007/7854_2015_377. View

Wingerchuk D, Carter J . Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014; 89(2):225-40. DOI: 10.1016/j.mayocp.2013.11.002. View

Habibi N, Kamaly N, Memic A, Shafiee H . Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery. Nano Today. 2016; 11(1):41-60. PMC: 4834907. DOI: 10.1016/j.nantod.2016.02.004. View

Rao S, Bushnell G, Azarin S, Spicer G, Aguado B, Stoehr J . Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo. Cancer Res. 2016; 76(18):5209-18. PMC: 5027988. DOI: 10.1158/0008-5472.CAN-15-2106. View

10.

Lalive P, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil S . Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011; 25(5):401-14. PMC: 3963480. DOI: 10.2165/11588120-000000000-00000. View

11.

Aharoni R, Schlegel P, Teitelbaum D, Chen Y, Arnon R, Sela M . Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. 1997; 58(2):79-87. DOI: 10.1016/s0165-2478(97)00032-1. View

12.

Kim J, Li W, Choi Y, Lewin S, Verbeke C, Dranoff G . Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2014; 33(1):64-72. PMC: 4318563. DOI: 10.1038/nbt.3071. View

13.

Zhang C, Zhai H, Yan Y, Hao J, Li M, Jin W . Glatiramer acetate ameliorates experimental autoimmune neuritis. Immunol Cell Biol. 2013; 92(2):164-9. DOI: 10.1038/icb.2013.81. View

14.

Varkony H, Weinstein V, Klinger E, Sterling J, Cooperman H, Komlosh T . The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother. 2009; 10(4):657-68. DOI: 10.1517/14656560902802877. View

15.

Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon O . Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A. 1994; 91(11):4872-6. PMC: 43891. DOI: 10.1073/pnas.91.11.4872. View

16.

Anderson J, Bell C, Bishop J, Capila I, Ganguly T, Glajch J . Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). J Neurol Sci. 2015; 359(1-2):24-34. DOI: 10.1016/j.jns.2015.10.007. View

17.

Kurnellas M, Adams C, Sobel R, Steinman L, Rothbard J . Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med. 2013; 5(179):179ra42. PMC: 3684024. DOI: 10.1126/scitranslmed.3005681. View

18.

Ali O, Emerich D, Dranoff G, Mooney D . In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med. 2010; 1(8):8ra19. PMC: 2872791. DOI: 10.1126/scitranslmed.3000359. View

19.

St John A, Chan C, Staats H, Leong K, Abraham S . Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater. 2012; 11(3):250-7. PMC: 3749235. DOI: 10.1038/nmat3222. View

20.

Kantengwa S, Weber M, Juillard C, Benkhoucha M, Fellay B, Zamvil S . Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol. 2007; 185(1-2):123-9. DOI: 10.1016/j.jneuroim.2006.12.014. View